|
|
| Home > Product > Pharmaceuticals > Genexol |
 |
|
|
|
|
|
|
|
|
 |
|
A chemotherapeutic agent with unique mechanism of action that extends new hope to patients
with refractory ovarian cancer and metastatic breast cancer.
Active Ingredient (per milliliter)
Paclitaxel ................... 6 mg
Indication
Metastatic carcinoma of ovary and breast after failure of first-line or subsequent chemotherapy.
Dosage and Administration
GENEXOL is administered at a dose of 175 mg/m?in 5% dextrose intravenously over 3 hours period
and repeated every three weeks has been shown to be effective.
Package
Paclitaxel 30mg / vial , 100mg / vial |
|
 |
 |
|
|
 |
|
Paclitaxel, a hydrophobic antineoplastic agent, is dissolved in 50% Polyoxyl 35 castor oil and 50%
dehydrated alcohol for I.V. injection in cancer treatment.
The clinical trials reveal the significant activities of paclitaxel for a wide range of human cancers,
including breast cancer,
ovarian cancer, non-small cell lung cancer, melanoma, Kaposi's sarcoma. |
 |
Nature has provided many excellent medicines to benefit the human health. There are many
effective anti-cancer agents in current use originating from nature , such as the microbially derived drugs;
dactinomycin, bleomycin and doxorubicin and the plant-derived drugs; vinblastine, irinotecan, topotecan,
etoposide, and paclitaxel. Paclitaxel may be one of the most important anticancer agents to be developed
over the past two decades. With its unique mechanism of action as an inducer of tubulin assembly,
paclitaxel has demonstrated impressive antitumor activity in patients with breast, lung (both non-small
cell and small cell), head and neck, and advanced and platinum-refractory ovarian carcinomas.
The advanced plant cell and tissue culture technology of Samyang Genex Co., assures non-polluting,
native friendly and unlimited supply of high quality Paclitaxel with very competitive cost. Scientific
evidences confirmed that Genexol? contains >99.0% pure Paclitaxel, the highest quality level of
Paclitaxel product.
Clinical trials in Korea since 1998 have proved the effectiveness and safety of Genexol?Paclitaxel)
Injection (which contains Paclitaxel fermented from Taxus chinensis) in breast cancer treatment.
|
|
 |
Customer services |
|
Person in charge : M.H. Kim
Address : 263 Yeonji-dong, Jongno-gu, Seoul 110-725, Korea
Tel : 82-2-740-7295 Fax : 82-2-743-6626
E-mail : marie@samyang.com |
|
|
|
|
|
|
|
|
|
|
|
